| pubmed-article:15809077 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15809077 | lifeskim:mentions | umls-concept:C0369335 | lld:lifeskim |
| pubmed-article:15809077 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:15809077 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15809077 | lifeskim:mentions | umls-concept:C1328949 | lld:lifeskim |
| pubmed-article:15809077 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:15809077 | lifeskim:mentions | umls-concept:C0128608 | lld:lifeskim |
| pubmed-article:15809077 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15809077 | pubmed:dateCreated | 2005-4-5 | lld:pubmed |
| pubmed-article:15809077 | pubmed:abstractText | Interferon (IFN)-alpha monotherapy, as well as the more effective combination therapy of IFN-alpha and ribavirin, are currently used for patients with chronic hepatitis C caused by hepatitis C virus (HCV) infection, although the mechanisms of the antiviral effects of these reagents on HCV remain ambiguous, and side effects such as anemia due to the administration of ribavirin present a problem for patients who are advanced in years. Using a recently developed reporter assay system in which genome-length dicistronic HCV RNA encoding Renilla luciferase gene was found to replicate efficiently, we found that mizoribine, an imidazole nucleoside, inhibited HCV RNA replication. The anti-HCV activity of mizoribine (IC50: approximately 100 microM) was similar to that of ribavirin. Using this genome-length HCV RNA replication monitor system, we were the first to demonstrate that the combination of IFN-alpha and ribavirin exhibited more effective anti-HCV activity than the use of IFN-alpha alone. Moreover, we found that the anti-HCV activity of mizoribine in co-treatment with IFN-alpha was at least equivalent to that of ribavirin. This effect was apparent in the presence of at least 5 microM mizoribine. Since mizoribine is currently used in several clinical applications and has not been associated with severe side effects, mizoribine is considered to be of potential use as a new anti-HCV reagent in combination with IFN-alpha. | lld:pubmed |
| pubmed-article:15809077 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15809077 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15809077 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15809077 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15809077 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15809077 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15809077 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15809077 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15809077 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15809077 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15809077 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15809077 | pubmed:month | May | lld:pubmed |
| pubmed-article:15809077 | pubmed:issn | 0006-291X | lld:pubmed |
| pubmed-article:15809077 | pubmed:author | pubmed-author:IkedaMasanori... | lld:pubmed |
| pubmed-article:15809077 | pubmed:author | pubmed-author:KatoNobuyukiN | lld:pubmed |
| pubmed-article:15809077 | pubmed:author | pubmed-author:AbeKen-ichiK | lld:pubmed |
| pubmed-article:15809077 | pubmed:author | pubmed-author:NakaKazuhitoK | lld:pubmed |
| pubmed-article:15809077 | pubmed:author | pubmed-author:DansakoHiromi... | lld:pubmed |
| pubmed-article:15809077 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15809077 | pubmed:day | 13 | lld:pubmed |
| pubmed-article:15809077 | pubmed:volume | 330 | lld:pubmed |
| pubmed-article:15809077 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15809077 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15809077 | pubmed:pagination | 871-9 | lld:pubmed |
| pubmed-article:15809077 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:meshHeading | pubmed-meshheading:15809077... | lld:pubmed |
| pubmed-article:15809077 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15809077 | pubmed:articleTitle | Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha. | lld:pubmed |
| pubmed-article:15809077 | pubmed:affiliation | Department of Molecular Biology, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. | lld:pubmed |
| pubmed-article:15809077 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15809077 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15809077 | lld:pubmed |
